Insider transactions

EDGAR

PROMIS NEUROSCIENCES INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
11 transactions, 752,466 shares
Sum of shares × price per share: 8,876,603.32
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–37 of 37

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-04 Filed 2026-11-06Williams Eugene Director
P

Open market or private purchase of non-derivative or derivative security

Common Shares
Acquired (A)26,5003.43
90,895

Derived: shares × price per share. Exact value 90895.00.

40,213Direct (D) No— Open filing 0001374339-26-000011 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-03Cashman Neil Director · Officer: Chief Scientific Officer
P

Open market or private purchase of non-derivative or derivative security

Common Shares
Acquired (A)10,0003.86
38,600

Derived: shares × price per share. Exact value 38600.00.

14,532Direct (D) No— Open filing 0001374339-26-000009 Read from the filing’s XML Dispute this row
2026-10-30 Filed 2026-11-03Williams Eugene Director
P

Open market or private purchase of non-derivative or derivative security

Common Shares
Acquired (A)1,3163.99
5,250.84

Derived: shares × price per share. Exact value 5250.84.

13,713Direct (D) No— Open filing 0001374339-26-000010 Read from the filing’s XML Dispute this row
2026-10-05 Filed 2026-10-06Rubino Ivana Officer: Chief Commercial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Shares (80,000) — exercise price 9.37
Acquired (A)80,0000—80,000Direct (D) No
F1
  • F1 25% of the shares subject to this option shall vest on October 5, 2026, with the remaining shares vesting monthly over the three (3) years thereafter, subject to continued service to the Issuer through each vesting date.
Open filing 0001104659-26-114106 Read from the filing’s XML Dispute this row
2026-08-05 Filed 2026-08-07Kaplan Johanne Officer: Chief Development Officer
P

Open market or private purchase of non-derivative or derivative security

Common Shares
Acquired (A)2,28013.3
30,324

Derived: shares × price per share. Exact value 30324.0.

6,221Direct (D) No— Open filing 0001104659-26-092673 Read from the filing’s XML Dispute this row
2026-05-20 Filed 2026-05-22Milbury Max A. Officer: Principal Accounting Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Shares (18,167) — exercise price 10.77
Acquired (A)18,1670—18,167Direct (D) No
F1
  • F1 The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date.
Open filing 0001104659-26-065766 Read from the filing’s XML Dispute this row
2026-05-20 Filed 2026-05-22Shafmaster Madge K. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Shares (5,500) — exercise price 10.77
Acquired (A)5,5000—5,500Direct (D) No
F1
  • F1 The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.
Open filing 0001104659-26-065771 Read from the filing’s XML Dispute this row
2026-05-20 Filed 2026-05-22Shafmaster Madge K. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Shares (11,000) — exercise price 10.77
Acquired (A)11,0000—11,000Direct (D) No
F2
  • F2 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.
Open filing 0001104659-26-065771 Read from the filing’s XML Dispute this row
2026-05-20 Filed 2026-05-22Warma Neil K Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Shares (160,000) — exercise price 10.77
Acquired (A)160,0000—160,000Direct (D) No
F1
  • F1 The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date.
Open filing 0001104659-26-065772 Read from the filing’s XML Dispute this row
2026-05-20 Filed 2026-05-22Kaplan Johanne Officer: Chief Development Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Shares (50,000) — exercise price 10.77
Acquired (A)50,0000—50,000Direct (D) No
F1
  • F1 The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date.
Open filing 0001104659-26-065762 Read from the filing’s XML Dispute this row
2026-05-20 Filed 2026-05-22Williams Eugene Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Shares (5,500) — exercise price 10.77
Acquired (A)5,5000—5,500Direct (D) No
F1
  • F1 The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.
Open filing 0001104659-26-065774 Read from the filing’s XML Dispute this row
2026-05-20 Filed 2026-05-22Williams Eugene Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Shares (11,000) — exercise price 10.77
Acquired (A)11,0000—11,000Direct (D) No
F2
  • F2 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.
Open filing 0001104659-26-065774 Read from the filing’s XML Dispute this row
2026-05-20 Filed 2026-05-22Alex Slanix Paul Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Shares (5,500) — exercise price 10.77
Acquired (A)5,5000—5,500Direct (D) No
F1
  • F1 The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.
Open filing 0001104659-26-065755 Read from the filing’s XML Dispute this row
2026-05-20 Filed 2026-05-22Alex Slanix Paul Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Shares (11,000) — exercise price 10.77
Acquired (A)11,0000—11,000Direct (D) No
F2
  • F2 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.
Open filing 0001104659-26-065755 Read from the filing’s XML Dispute this row
2026-05-20 Filed 2026-05-22Mandel-Brehm Josh Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Shares (5,500) — exercise price 10.77
Acquired (A)5,5000—5,500Direct (D) No
F1
  • F1 The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.
Open filing 0001104659-26-065763 Read from the filing’s XML Dispute this row
2026-05-20 Filed 2026-05-22Mandel-Brehm Josh Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Shares (11,000) — exercise price 10.77
Acquired (A)11,0000—11,000Direct (D) No
F2
  • F2 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.
Open filing 0001104659-26-065763 Read from the filing’s XML Dispute this row
2026-05-20 Filed 2026-05-22WYMAN WILLIAM W Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Shares (5,500) — exercise price 10.77
Acquired (A)5,5000—5,500Direct (D) No
F1
  • F1 The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.
Open filing 0001104659-26-065775 Read from the filing’s XML Dispute this row
2026-05-20 Filed 2026-05-22WYMAN WILLIAM W Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Shares (11,000) — exercise price 10.77
Acquired (A)11,0000—11,000Direct (D) No
F2
  • F2 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.
Open filing 0001104659-26-065775 Read from the filing’s XML Dispute this row
2026-05-20 Filed 2026-05-22Cashman Neil Director · Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Shares (50,000) — exercise price 10.77
Acquired (A)50,0000—50,000Direct (D) No
F1
  • F1 The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date.
Open filing 0001104659-26-065769 Read from the filing’s XML Dispute this row
2026-04-22 Filed 2026-04-23Kirwin Patrick D. Director
P

Open market or private purchase of non-derivative or derivative security

Common Shares
Acquired (A)4,00011.33
45,320

Derived: shares × price per share. Exact value 45320.00.

4,653Indirect (I) By Patrick D. Kirwin Professional CorpNo— Open filing 0001104659-26-047977 Read from the filing’s XML Dispute this row
2026-03-05 Filed 2026-03-06Williams Eugene Director
P

Open market or private purchase of non-derivative or derivative security

Common Shares
Acquired (A)2,00024.4
48,800

Derived: shares × price per share. Exact value 48800.0.

12,397Direct (D) No— Open filing 0001374339-26-000004 Read from the filing’s XML Dispute this row
2026-03-04 Filed 2026-03-04Williams Eugene Director
P

Open market or private purchase of non-derivative or derivative security

Common Shares
Acquired (A)2,00024
48,000

Derived: shares × price per share. Exact value 48000.

10,397Direct (D) No— Open filing 0001374339-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-04Williams Eugene Director
P

Open market or private purchase of non-derivative or derivative security

Common Shares
Acquired (A)1,00021.89
21,890

Derived: shares × price per share. Exact value 21890.00.

8,397Direct (D) No— Open filing 0001374339-26-000003 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-03-04Williams Eugene Director
P

Open market or private purchase of non-derivative or derivative security

Common Shares
Acquired (A)1,00022.53
22,530

Derived: shares × price per share. Exact value 22530.00.

7,397Direct (D) No— Open filing 0001374339-26-000003 Read from the filing’s XML Dispute this row
2026-02-19 Filed 2026-02-23Kaplan Johanne Officer: Chief Development Officer
P

Open market or private purchase of non-derivative or derivative security

Common Shares
Acquired (A)1,62915.35
25,005.15

Derived: shares × price per share. Exact value 25005.15.

3,941Direct (D) No— Open filing 0001374339-26-000002 Read from the filing’s XML Dispute this row
2026-02-03 Filed 2026-02-05Warma Neil K Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Shares
Acquired (A)6,18312.13
74,999.79

Derived: shares × price per share. Exact value 74999.79.

6,183Direct (D) No
F1
  • F1 On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,183 of the Company's common shares, no par value (the Common Shares) and Common Share purchase warrants (the Common Share Warrants) to purchase 6,183 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.
Open filing 0001104659-26-011138 Read from the filing’s XML Dispute this row
2026-02-03 Filed 2026-02-05Warma Neil K Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Warrants to purchase Common Shares — underlying Common Shares (6,183) — exercise price 14.40
Acquired (A)6,183——6,183Direct (D) No
F1, F2
  • F1 On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,183 of the Company's common shares, no par value (the Common Shares) and Common Share purchase warrants (the Common Share Warrants) to purchase 6,183 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.
  • F2 The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.
Open filing 0001104659-26-011138 Read from the filing’s XML Dispute this row
2026-02-03 Filed 2026-02-05Milbury Max A. Other: Principal Accounting Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Shares
Acquired (A)6,59512.13
79,997.35

Derived: shares × price per share. Exact value 79997.35.

8,409Direct (D) No
F1, F2
  • F1 On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,595 of the Company's common shares, no par value (the Common Shares) and Common Share purchase warrants (the Common Share Warrants) to purchase 6,595 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.
  • F2 Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025.
Open filing 0001104659-26-011137 Read from the filing’s XML Dispute this row
2026-02-03 Filed 2026-02-05Milbury Max A. Other: Principal Accounting Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Warrants to purchase Common Shares — underlying Common Shares (6,595) — exercise price 14.40
Acquired (A)6,595——6,595Direct (D) No
F1, F3
  • F1 On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,595 of the Company's common shares, no par value (the Common Shares) and Common Share purchase warrants (the Common Share Warrants) to purchase 6,595 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.
  • F3 The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.
Open filing 0001104659-26-011137 Read from the filing’s XML Dispute this row
2026-02-03 Filed 2026-02-05ABG Management Ltd. 10% ownerAlly Bridge MedAlpha Master Fund L.P. 10% ownerAlly Bridge Group (NY) LLC 10% ownerYu Fan 10% ownerAlex Slanix Paul Director
P

Open market or private purchase of non-derivative or derivative security

Common Shares
Acquired (A)700,74112.13
8,499,988.33

Derived: shares × price per share. Exact value 8499988.33.

943,090Indirect (I) See FootnoteNo
F1, F2, F3, F4, F5
  • F1 The Warrants were purchased together with the Common Shares reported herein for an aggregate purchase price of $12.13 per Common Share.
  • F2 The Common Shares reported herein include: (i) 407,230 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) 206,100 Common Shares held of record by ABG V-SIV X Limited.
  • F3 Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P.
  • F4 Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited.
  • F5 Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited.
Open filing 0001493152-26-005410 Read from the filing’s XML Dispute this row
2026-02-03 Filed 2026-02-05ABG Management Ltd. 10% ownerAlly Bridge MedAlpha Master Fund L.P. 10% ownerAlly Bridge Group (NY) LLC 10% ownerYu Fan 10% ownerAlex Slanix Paul Director
P

Open market or private purchase of non-derivative or derivative security

Derivative security: Warrants — underlying Common Shares (700,741) — exercise price 14.40
Acquired (A)700,741——700,741Indirect (I) See FootnoteNo
F1, F6, F3, F4, F5, F7
  • F1 The Warrants were purchased together with the Common Shares reported herein for an aggregate purchase price of $12.13 per Common Share.
  • F6 The warrants to purchase Common Shares (the Warrants) are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event or (ii) February 3, 2031. For purposes of the foregoing, the Milestone Event means the public announcement via press release or the filing of a Current Report on Form 8-K by the Issuer of topline data from the cohorts treated with single ascending doses of PMN310.
  • F3 Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P.
  • F4 Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited.
  • F5 Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited.
  • F7 The Warrants reported herein include: (i) Warrants to purchase 164,881 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) Warrants to purchase 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) Warrants to purchase 206,100 Common Shares held of record by ABG V-SIV X Limited.
Open filing 0001493152-26-005410 Read from the filing’s XML Dispute this row
2026-02-03 Filed 2026-02-05Kirwin Patrick D. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Shares
Acquired (A)3,05012.13
36,996.5

Derived: shares × price per share. Exact value 36996.50.

5,135Direct (D) No
F1, F2
  • F1 On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 3,050 of the Company's common shares, no par value (the Common Shares) and Common Share purchase warrants (the Common Share Warrants) to purchase 3,050 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.
  • F2 Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025.
Open filing 0001104659-26-011135 Read from the filing’s XML Dispute this row
2026-02-03 Filed 2026-02-05Kirwin Patrick D. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Warrants to purchase Common Shares — underlying Common Shares (3,050) — exercise price 14.40
Acquired (A)3,050——3,050Direct (D) No
F1, F3
  • F1 On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 3,050 of the Company's common shares, no par value (the Common Shares) and Common Share purchase warrants (the Common Share Warrants) to purchase 3,050 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.
  • F3 The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.
Open filing 0001104659-26-011135 Read from the filing’s XML Dispute this row
2026-02-03 Filed 2026-02-05Cashman Neil Director · Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Shares
Acquired (A)4,12212.13
49,999.86

Derived: shares × price per share. Exact value 49999.86.

4,122Indirect (I) By Research Capital CorporationNo
F1
  • F1 On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 4,122 of the Company's common shares, no par value (the Common Shares) and Common Share purchase warrants (the Common Share Warrants) to purchase 4,122 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.
Open filing 0001104659-26-011140 Read from the filing’s XML Dispute this row
2026-02-03 Filed 2026-02-05Cashman Neil Director · Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Warrants to purchase Common Shares — underlying Common Shares (4,122) — exercise price 14.40
Acquired (A)4,122——4,122Indirect (I) By Research Capital CorporationNo
F1, F3
  • F1 On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 4,122 of the Company's common shares, no par value (the Common Shares) and Common Share purchase warrants (the Common Share Warrants) to purchase 4,122 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.
  • F3 The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.
Open filing 0001104659-26-011140 Read from the filing’s XML Dispute this row
2026-02-03 Filed 2026-02-05Kaplan Johanne Officer: Chief Development Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Shares
Acquired (A)2,06012.13
24,987.8

Derived: shares × price per share. Exact value 24987.80.

2,312Direct (D) No
F1, F2
  • F1 On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 2,060 of the Company's common shares, no par value (the Common Shares) and Common Share purchase warrants (the Common Share Warrants) to purchase 2,060 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.
  • F2 Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025.
Open filing 0001104659-26-011139 Read from the filing’s XML Dispute this row
2026-02-03 Filed 2026-02-05Kaplan Johanne Officer: Chief Development Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Warrants to purchase Common Shares — underlying Common Shares (2,060) — exercise price 14.40
Acquired (A)2,060——2,060Direct (D) No
F1, F3
  • F1 On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 2,060 of the Company's common shares, no par value (the Common Shares) and Common Share purchase warrants (the Common Share Warrants) to purchase 2,060 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.
  • F3 The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.
Open filing 0001104659-26-011139 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–31 of 31

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Janus Henderson Group Ltd. Partly reported under another manager1,292,657 SH14,089,961 dollarsNot in the prior quarter’s filings read Open filing 0001085146-26-000952 Filed 2026-11-16 Dispute this row
Deep Track Capital, LP 740,117 SH8,030,269 dollarsLower by 95,538 Prior quarter: 835,655Open filing 0001856083-26-000006 Filed 2026-11-16 Dispute this row
WELLINGTON MANAGEMENT GROUP LLP Partly reported under another manager696,378 SH7,555,701 dollarsUnchanged Prior quarter: 696,378Open filing 0000902219-26-000323 Filed 2026-11-16 Dispute this row
Ally Bridge Group (NY) LLC 620,319 SH6,730,461 dollarsUnchanged Prior quarter: 620,319Open filing 0001193125-26-463652 Filed 2026-11-16 Dispute this row
ADAGE CAPITAL PARTNERS GP, L.L.C. 564,275 SH6,122,384 dollarsHigher by 400,000 Prior quarter: 164,275Open filing 0001172661-26-005200 Filed 2026-11-16 Dispute this row
Trails Edge Capital Partners, LP 557,103 SH6,044,568 dollarsUnchanged Prior quarter: 557,103Open filing 0002077247-26-000005 Filed 2026-11-16 Dispute this row
Yu Fan 329,760 SH3,577,896 dollarsUnchanged Prior quarter: 329,760Open filing 0001193125-26-463618 Filed 2026-11-16 Dispute this row
Woodline Partners LP 314,601 SH3,413,421 dollarsLower by 127,310 Prior quarter: 441,911Open filing 0001172661-26-005063 Filed 2026-11-16 Dispute this row
SPHERA FUNDS MANAGEMENT LTD. Partly reported under another manager254,782 SH2,764,390 dollarsLower by 70,809 Prior quarter: 325,591Open filing 0001496201-26-000006 Filed 2026-11-16 Dispute this row
683 Capital Management, LLC Partly reported under another manager250,000 SH2,712,500 dollarsHigher by 155,000 Prior quarter: 95,000Open filing 0001404574-26-000027 Filed 2026-11-16 Dispute this row
Ikarian Capital, LLC 205,000 SH2,224,250 dollarsUnchanged Prior quarter: 205,000Open filing 0001420506-26-002881 Filed 2026-11-16 Dispute this row
AMERIPRISE FINANCIAL INC Partly reported under another manager185,700 SH2,014,845 dollarsUnchanged Prior quarter: 185,700Open filing 0001193125-26-463125 Filed 2026-11-16 Dispute this row
MILLENNIUM MANAGEMENT LLC 121,123 SH1,314,185 dollarsHigher by 65,078 Prior quarter: 56,045Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
ADAR1 Capital Management, LLC 92,850 SH976,782 dollarsUnchanged Prior quarter: 92,850Open filing 0001940272-26-000033 Filed 2026-11-16 Dispute this row
BOOTHBAY FUND MANAGEMENT, LLC 62,078 SH673,546 dollarsUnchanged Prior quarter: 62,078Open filing 0001549230-26-000012 Filed 2026-11-16 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager22,902 SH248,487 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
TWO SIGMA INVESTMENTS, LP 16,228 SH176,074 dollarsNot in the prior quarter’s filings read Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
JANE STREET GROUP, LLC Partly reported under another manager14,621 SH158,638 dollarsNot in the prior quarter’s filings read Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
Quadrature Capital Ltd Partly reported under another manager11,615 SH126,023 dollarsNot in the prior quarter’s filings read Open filing 0001651424-26-000014 Filed 2026-11-13 Dispute this row
Seven Fleet Capital Management LP 10,600 SH115,010 dollarsUnchanged Prior quarter: 10,600Open filing 0001013594-26-001198 Filed 2026-11-16 Dispute this row
MORGAN STANLEY Partly reported under another manager7,559 SH82,015 dollarsUnchanged Prior quarter: 7,559Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
OSAIC HOLDINGS, INC. Partly reported under another manager360 SH3,906 dollarsUnchanged Prior quarter: 360Open filing 0001677044-26-000011 Filed 2026-11-12 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager285 SH3,118 dollarsNot in the prior quarter’s filings read Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
ROYAL BANK OF CANADA Partly reported under another manager218 SH2,000 dollarsUnchanged Prior quarter: 218Open filing 0001140361-26-044123 Filed 2026-11-16 Dispute this row
Steward Partners Investment Advisory, LLC 94 SH1,020 dollarsUnchanged Prior quarter: 94Open filing 0001723397-26-000006 Filed 2026-11-13 Dispute this row
Tower Research Capital LLC (TRC) Partly reported under another manager33 SH358 dollarsNot in the prior quarter’s filings read Open filing 0001533421-26-000010 Filed 2026-11-16 Dispute this row
Federation des caisses Desjardins du Quebec 10 SH108 dollarsUnchanged Prior quarter: 10Open filing 0002022297-26-000010 Filed 2026-11-16 Dispute this row
Caitong International Asset Management Co., Ltd 10 SH108 dollarsHigher by 7 Prior quarter: 3Open filing 0001628280-26-068135 Filed 2026-10-29 Dispute this row
TD Waterhouse Canada Inc. Partly reported under another manager5 SH46 dollarsUnchanged Prior quarter: 5Open filing 0002052595-26-000100 Filed 2026-10-16 Dispute this row
NATIONAL BANK OF CANADA /FI/ Partly reported under another manager2 SH22 dollarsNot in the prior quarter’s filings read Open filing 0000926171-26-000014 Filed 2026-11-16 Dispute this row
UBS Group AG Partly reported under another manager1 SH11 dollarsLower by 690 Prior quarter: 691Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Jupiter Topco LLC 1,292,757 SH
  • Squadron Capital Management LLC 324,977 SH
  • GREAT POINT PARTNERS LLC 86,150 SH
  • BANK OF MONTREAL /CAN/ 11,371 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Great Point Partners, LLC Common Shares, No Par Value per Share6.77650,731.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001172661-26-005410 Dispute this row
Dr. Jeffrey R. Jay, M.D. Common Shares, No Par Value per Share6.77650,731.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001172661-26-005410 Dispute this row
Ms. Lillian Nordahl Common Shares, No Par Value per Share6.77650,731.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001172661-26-005410 Dispute this row
Adage Capital Management, L.P. Common Shares, no par value per share7.73703,550.0009/30/2026 Filed 2026-11-12SCHEDULE 13GOpen filing 0000919574-26-007569 Dispute this row
Robert Atchinson Common Shares, no par value per share7.73703,550.0009/30/2026 Filed 2026-11-12SCHEDULE 13GOpen filing 0000919574-26-007569 Dispute this row
Phillip Gross Common Shares, no par value per share7.73703,550.0009/30/2026 Filed 2026-11-12SCHEDULE 13GOpen filing 0000919574-26-007569 Dispute this row
Great Point Partners, LLC Common Shares, No Par Value per Share7.66736,881.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001172661-26-003535 Dispute this row
Dr. Jeffrey R. Jay, M.D. Common Shares, No Par Value per Share7.66736,881.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001172661-26-003535 Dispute this row
Ms. Lillian Nordahl Common Shares, No Par Value per Share7.66736,881.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001172661-26-003535 Dispute this row
Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. Common Stock7.8696,378.0006/30/2026 Filed 2026-08-13SCHEDULE 13G/AAmendment 1Open filing 0001903360-26-000014 Dispute this row
Wellington Management Group LLP Common Stock7.8696,378.0006/30/2026 Filed 2026-08-13SCHEDULE 13G/AAmendment 1Open filing 0000902219-26-000224 Dispute this row
Wellington Group Holdings LLP Common Stock7.8696,378.0006/30/2026 Filed 2026-08-13SCHEDULE 13G/AAmendment 1Open filing 0000902219-26-000224 Dispute this row
Wellington Investment Advisors Holdings LLP Common Stock7.8696,378.0006/30/2026 Filed 2026-08-13SCHEDULE 13G/AAmendment 1Open filing 0000902219-26-000224 Dispute this row
Wellington Management Company LLP Common Stock7.8696,378.0006/30/2026 Filed 2026-08-13SCHEDULE 13G/AAmendment 1Open filing 0000902219-26-000224 Dispute this row
Wellington Management Group LLP Common Stock10.0895,871.0003/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0000902219-26-000122 Dispute this row
Wellington Group Holdings LLP Common Stock10.0895,871.0003/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0000902219-26-000122 Dispute this row
Wellington Investment Advisors Holdings LLP Common Stock10.0895,871.0003/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0000902219-26-000122 Dispute this row
Wellington Management Company LLP Common Stock10.0895,871.0003/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0000902219-26-000122 Dispute this row
Great Point Partners, LLC Common Shares, No Par Value per Share9.99954,082.0003/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0001172661-26-002037 Dispute this row
Dr. Jeffrey R. Jay, M.D. Common Shares, No Par Value per Share9.99954,082.0003/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0001172661-26-002037 Dispute this row
Ms. Lillian Nordahl Common Shares, No Par Value per Share9.99954,082.0003/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0001172661-26-002037 Dispute this row
Michael S. Gordon Common Shares, No Par Value2.0181,632.0003/31/2026 Filed 2026-05-07SCHEDULE 13G/AAmendment 5Open filing 0001104659-26-057168 Dispute this row
Title 19 Promis Common Shares, No Par Value2.0181,632.0003/31/2026 Filed 2026-05-07SCHEDULE 13G/AAmendment 5Open filing 0001104659-26-057168 Dispute this row
JANUS HENDERSON GROUP PLC Common Shares14.41,292,75703/31/2026 Filed 2026-04-07SCHEDULE 13GOpen filing 0001274173-26-000104 Dispute this row
Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. Common Stock9.99895,877.0003/11/2026 Filed 2026-03-18SCHEDULE 13GOpen filing 0001903360-26-000013 Dispute this row
Trails Edge Capital Partners, LP Common Shares, no par value per share9.9933,477.0002/03/2026 Filed 2026-02-10SCHEDULE 13GOpen filing 0001493152-26-005965 Dispute this row
Trails Edge Biotechnology Master Fund, LP Common Shares, no par value per share9.9933,477.0002/03/2026 Filed 2026-02-10SCHEDULE 13GOpen filing 0001493152-26-005965 Dispute this row
Ortav Yehudai Common Shares, no par value per share9.9933,477.0002/03/2026 Filed 2026-02-10SCHEDULE 13GOpen filing 0001493152-26-005965 Dispute this row
ABG Management Ltd. Common Shares, no par value per share6.3572,677.0002/03/2026 Filed 2026-02-05SCHEDULE 13D/AAmendment 2Open filing 0001493152-26-005412 Dispute this row
Ally Bridge Group (NY) LLC Common Shares, no par value per share6.3572,677.0002/03/2026 Filed 2026-02-05SCHEDULE 13D/AAmendment 2Open filing 0001493152-26-005412 Dispute this row
Ally Bridge MedAlpha Master Fund L.P. Common Shares, no par value per share6.3572,677.0002/03/2026 Filed 2026-02-05SCHEDULE 13D/AAmendment 2Open filing 0001493152-26-005412 Dispute this row
ABG V-SIV IX Limited Common Shares, no par value per share7.1659,520.0002/03/2026 Filed 2026-02-05SCHEDULE 13D/AAmendment 2Open filing 0001493152-26-005412 Dispute this row
Ally Bridge Group Global Life Science Capital Partners V, L.P. Common Shares, no par value per share7.1659,520.0002/03/2026 Filed 2026-02-05SCHEDULE 13D/AAmendment 2Open filing 0001493152-26-005412 Dispute this row
ABG Global Life Science Capital Partners V GP, L.P. Common Shares, no par value per share7.1659,520.0002/03/2026 Filed 2026-02-05SCHEDULE 13D/AAmendment 2Open filing 0001493152-26-005412 Dispute this row
ABG Global Life Science Capital Partners V GP Limited Common Shares, no par value per share7.1659,520.0002/03/2026 Filed 2026-02-05SCHEDULE 13D/AAmendment 2Open filing 0001493152-26-005412 Dispute this row
ABG V-SIV X Limited Common Shares, no par value per share4.5412,200.0002/03/2026 Filed 2026-02-05SCHEDULE 13D/AAmendment 2Open filing 0001493152-26-005412 Dispute this row
Fan Yu Common Shares, no par value per share17.01,644,397.0002/03/2026 Filed 2026-02-05SCHEDULE 13D/AAmendment 2Open filing 0001493152-26-005412 Dispute this row
Deep Track Capital, LP Common Shares, no par value per share9.99902,561.0001/30/2026 Filed 2026-02-06SCHEDULE 13GOpen filing 0001172661-26-000524 Dispute this row
Deep Track Biotechnology Master Fund, Ltd. Common Shares, no par value per share7.79703,457.0001/30/2026 Filed 2026-02-06SCHEDULE 13GOpen filing 0001172661-26-000524 Dispute this row
David Kroin Common Shares, no par value per share9.99902,561.0001/30/2026 Filed 2026-02-06SCHEDULE 13GOpen filing 0001172661-26-000524 Dispute this row
Deep Track Special Opportunities Fund, LP. Common Shares, no par value per share2.20199,104.0001/30/2026 Filed 2026-02-06SCHEDULE 13GOpen filing 0001172661-26-000524 Dispute this row
ABG Management Ltd. Common Shares, no par value per share11.36,070,405.0001/29/2026 Filed 2026-02-02SCHEDULE 13D/AAmendment 1Open filing 0001493152-26-004760 Dispute this row
Ally Bridge Group (NY) LLC Common Shares, no par value per share11.36,070,405.0001/29/2026 Filed 2026-02-02SCHEDULE 13D/AAmendment 1Open filing 0001493152-26-004760 Dispute this row
Ally Bridge MedAlpha Master Fund L.P. Common Shares, no par value per share11.36,070,405.0001/29/2026 Filed 2026-02-02SCHEDULE 13D/AAmendment 1Open filing 0001493152-26-004760 Dispute this row
Fan Yu Common Shares, no par value per share11.36,070,405.0001/29/2026 Filed 2026-02-02SCHEDULE 13D/AAmendment 1Open filing 0001493152-26-004760 Dispute this row
Great Point Partners, LLC Common Shares, no par value per share9.99409,648.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 5Open filing 0001172661-26-001139 Dispute this row
Dr. Jeffrey R. Jay, M.D. Common Shares, no par value per share9.99409,648.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 5Open filing 0001172661-26-001139 Dispute this row
Ms. Lillian Nordahl Common Shares, no par value per share9.99409,648.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 5Open filing 0001172661-26-001139 Dispute this row
Armistice Capital, LLC Common Shares, no par value per share0.93504,673.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 4Open filing 0001172661-26-001223 Dispute this row
Steven Boyd Common Shares, no par value per share0.93504,673.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 4Open filing 0001172661-26-001223 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,715,586 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015131,968
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to PROMIS NEUROSCIENCES INC.